Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
Leslie W. Tari(Arcturus Therapeutics (United States)), John Finn(Arcturus Therapeutics (United States)), Michael Trzoss(Arcturus Therapeutics (United States)), Mark A. Stidham(Arcturus Therapeutics (United States)), Thanh Lam(Arcturus Therapeutics (United States)), Jay C. Nix(Lawrence Berkeley National Laboratory), Bryan P. Kwan(Arcturus Therapeutics (United States)), Christopher J. Creighton(Arcturus Therapeutics (United States)), Daniel C. Bensen(State Street (United States)), Karen Joy Shaw(Arcturus Therapeutics (United States)), Xiaoming Li(Qiqihar Medical University), Zhiyong Chen(Arcturus Therapeutics (United States)), Toan B. Nguyen(Lawrence Livermore National Laboratory), Mark L. Cunningham(Arcturus Therapeutics (United States)), Felice C. Lightstone, Sergio Wong(Lawrence Livermore National Laboratory), Junhu Zhang(Jilin University)
Cited by 118
Related Papers
The photoluminescence mechanism in carbon dots (graphene quantum dots, carbon nanodots, and polymer dots): current state and future perspective
|Nano Research|2015|2.7k
Surface Chemistry Routes to Modulate the Photoluminescence of Graphene Quantum Dots: From Fluorescence Mechanism to Up‐Conversion Bioimaging Applications
|Advanced Functional Materials|2012|1.1k